Clinical Trials Logo

Clinical Trial Summary

Transcatheter aortic valve implantation (TAVI) is a well-established alternative to surgical aortic valve replacement for the treatment of patients with symptomatic severe aortic stenosis. While peri-procedural complications such as stroke, vascular complications and bleeding have substantially declined with the refinement of transcatheter valves and increasing experience, new-onset atrial fibrillation (NOAF) or atrioventricular conduction disturbances continue to occur in almost half of all patients. Colchicine is a well-known substance that has been approved for the treatment of acute gout flares and familial Mediterranean fever in many countries. Colchicine has proven safe and effective in the prevention of atrial fibrillation after cardiac surgery. The anti-inflammatory effects of colchicine may mitigate the occurrence of atrioventricular conduction disturbances and thus the need for the implantation of a permanent pacemaker post transcatheter aortic valve implantation. The objective of the Co-STAR-Trial is to investigate the efficacy of colchicine for the prevention of new-onset atrial fibrillation and conduction disturbances requiring the implantation of a permanent pacemaker in patients undergoing transcatheter aortic valve implantation. Co-STAR is an investigator-initiated, randomized, double blind, placebo-controlled trial. A total of 200 patients referred for treatment of symptomatic severe aortic stenosis and selected to undergo TAVI will be randomized in a 1:1 ratio to the treatment with Colchicine or placebo for 30 days post transcatheter aortic valve implantation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04870424
Study type Interventional
Source Insel Gruppe AG, University Hospital Bern
Contact Thomas Pilgrim, Prof.
Phone +41 31 632 08 27
Email thomas.pilgrim@insel.ch
Status Recruiting
Phase Phase 3
Start date September 21, 2021
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05465655 - Cara CDRM (Conduction Disturbance Risk Monitor) 2.0 N/A
Completed NCT02758964 - Evaluation of Cerebral Thrombembolism After TAVR
Recruiting NCT05758701 - CT TAVR Abdomen Study Phase 4
Active, not recruiting NCT04281771 - Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement Phase 4
Recruiting NCT05235555 - EffecTAVI Registry
Completed NCT05082337 - The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures N/A
Completed NCT01627691 - REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System N/A
Recruiting NCT05075590 - Coronary Access After Supra-Annular THV Implantation N/A
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Recruiting NCT05259241 - ADAPT Transcatheter Aortic Valve Intervention (TAVI & Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) N/A
Completed NCT04489914 - Observational Study on the Application of High-Flow Therapy After Percutaneous Transfemoral Aortic Valve Replacement
Recruiting NCT03649594 - Risk Stratification Post TAVI Using TEG
Completed NCT04659538 - The CAPTIS® Study - Embolic Protection in TAVR N/A
Recruiting NCT04107038 - Monitored Anesthesia Care vs. General Anesthesia for Transcatheter Aortic Valve Replacement N/A
Withdrawn NCT04268160 - GPx Activity in Subjects With Aortic Stenosis Undergoing TAVR
Recruiting NCT02812953 - Biological Collection and Registry of Patients Who Will Have a TAVR (Transcatheter Aortic Valve Replacement) Intervention
Recruiting NCT05217888 - The Sentinel Registry
Recruiting NCT04982406 - Transcatheter Aortic Valve Replacement (TAVR) Effects on Cardiac Conduction System